chr3-52403251-G-A
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_004656.4(BAP1):c.1777C>T(p.Gln593*) variant causes a stop gained change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_004656.4 stop_gained
Scores
Clinical Significance
Conservation
Publications
- BAP1-related tumor predisposition syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Ambry Genetics, G2P, Orphanet, Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- Kury-Isidor syndromeInheritance: AD Classification: STRONG, MODERATE Submitted by: Ambry Genetics, G2P
- renal cell carcinomaInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| BAP1 | NM_004656.4 | c.1777C>T | p.Gln593* | stop_gained | Exon 14 of 17 | ENST00000460680.6 | NP_004647.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
BAP1-related tumor predisposition syndrome Pathogenic:3
This sequence change creates a premature translational stop signal (p.Gln593*) in the BAP1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BAP1 are known to be pathogenic (PMID: 21874000, 23684012). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with BAP1 tumor predisposition syndrome (PMID: 26774355). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 422219). For these reasons, this variant has been classified as Pathogenic. -
The c.1777C>T variant is predicted to cause a nonsense change at residue 593 of the BAP1 protein. It is absent from large public databases including gnomAD, and has been recently reported as pathogenic by multiple clinical laboratories. This variant was observed in a mother and daughter who developed meningiomas with rhabdoid features. We interpret the variant as pathogenic. -
- -
not provided Pathogenic:2
This variant is denoted BAP1 c.1777C>T at the cDNA level and p.Gln593Ter (Q593X) at the protein level. The substitution creates a nonsense variant, which changes a Glutamine to a premature stop codon (CAG>TAG), and is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. McDonnell et al (2016) identified BAP1 Gln593Ter in an individual with a personal history of melanoma, thyroid neoplasia, basal cell carcinoma, and lymphoma and a family history of Spitz nevi, melanoma, and other cancers. Tumors from the proband and her sons demonstrated loss of the BAP1 protein by immunohistochemistry, and this variant segregated with disease in the family. We consider this variant to be pathogenic. -
The BAP1 c.1777C>T (p.Gln593*) variant causes the premature termination of BAP1 protein synthesis. This variant has been reported in the published literature in individuals with meningioma (PMID: 34628055 (2022)), melanoma (PMID: 31887429 (2020)). The variant also has been observed in an individual with multiple cancers such as papillary thyroid cancer, b-cell lymphoma, and basal cell carcinoma (PMID: 26774355 (2016)). This variant has not been reported in large, multi-ethnic general populations (Genome Aggregation Database, http://gnomad.broadinstitute.org). Based on the available information, this variant is classified as pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.Q593* pathogenic mutation (also known as c.1777C>T), located in coding exon 14 of the BAP1 gene, results from a C to T substitution at nucleotide position 1777. This changes the amino acid from a glutamine to a stop codon within coding exon 14. This variant has been described multiple individuals diagnosed with BAP1-related cancers (McDonnell KJ et al. Cancer Genet, 2016 Mar;209:75-81; Garfield EM et al. J Am Acad Dermatol, 2018 Sep;79:525-534; Guo R et al. J Thorac Oncol, 2020 04;15:655-660). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at